secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0001326110-23-000076
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio signs $30M promissory note with Nant Capital (SOFR+8%, due Dec 31, 2023)
--------------------------------------------------------------------------------

- Three $10M advances available; interest at Term SOFR + 8% per annum payable quarterly.
- Net proceeds ~$29.85M after $150k origination fee (0.5%) paid to lender.
- Proceeds to fund pre-commercialization, clinical development, R&D, capex, and general corporate purposes.
- Lender Nant Capital is affiliate of Executive Chairman Dr. Patrick Soon-Shiong (related-party transaction).
- Annual meeting results: all nine director nominees re-elected; Ernst & Young ratified as auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/ibrx-20230613.htm
  HTML page:      https://secwatch.observer/filing/0001326110-23-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer